Successful use of vemurafenib in a patient with resistant hairy cell leukemia
- Authors: Urnova ES1, Al'-Radi LS1, Kuz'mina LA1, Kariakina AA1, Kovrigina AM1, Dvirnyk VN1, Iakutik IA1, Sudarikov AB1, Parovichnikova EN1, Savchenko VG1
-
Affiliations:
- Гематологический научный центр Минздрава России, Москва
- Issue: Vol 85, No 7 (2013)
- Pages: 76-78
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31323
- ID: 31323
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
E S Urnova
Гематологический научный центр Минздрава России, Москва
Email: Eurnova@mail.ru
L S Al'-Radi
Гематологический научный центр Минздрава России, Москва
L A Kuz'mina
Гематологический научный центр Минздрава России, Москва
A A Kariakina
Гематологический научный центр Минздрава России, Москва
A M Kovrigina
Гематологический научный центр Минздрава России, Москва
V N Dvirnyk
Гематологический научный центр Минздрава России, Москва
I A Iakutik
Гематологический научный центр Минздрава России, Москва
A B Sudarikov
Гематологический научный центр Минздрава России, Москва
E N Parovichnikova
Гематологический научный центр Минздрава России, Москва
V G Savchenko
Гематологический научный центр Минздрава России, Москва
References
- Аль-Ради Л.С., Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. Клин онкогематол 2009; 2: 111-120.
- Аль-Ради Л.С., Пивник А.В., Зингерман Б.В., Кравченко С.К. Лечение рецидивов волосатоклеточного лейкоза. Тер арх 2012; 7: 4-9.
- Волкова М.А. Волосатоклеточный лейкоз. В кн: Клиническая онкогематология. Руководство для врачей, 2-е изд. Под ред. М.А. Волкова М: Медицина 2007: 396-410.
- Catovsky D., O'Brien M., Melo J.V. et al. Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 1984; 11: 362-369.
- Matutes E., Morilla R., Owusu-Ankomah K. et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia & Lymphoma 1994; 14 suppl 1: 57-61.
- Bouroncle B., Wiseman B., Doan C. Leukemic reticuloendotheliosis. Blood 1958; 13: 609-630.
- Matutes E., Wotherspoon A., Catovsky D. The variant form of hairy-cell leukaemia. In Best Pract & Res Clin Haematol 2003; 16 (1): 41-56.
- Tiacci E., Trifonov V., Schiavoni G. et al. BRAF Mutations in Hairy-Cell Leukemia. N Engl J Med 2011; 364: 2305-2315.
- Dicker F., Eder C., Jeromin S. et al. BRAFV600E negative hairy cell leukemia is rare and not associated with specific IGHV rearrangements or a specific IGHV mutation status. Haematologica 2012; 97: e-Supplement 1: 377.
- Thompson J. Past and present role of interferon in hairy cell leukemia. In: Advances in Blood Disorders series. M.S. Tallman, A. Pulliack (eds.) V. 5. Harwood academic Publishers 2000: 127-139.
- Rai K., Davey F., Peterson B. et al. Recobinant α-2b interferon in therapy of previously untreated hairy cell leukemia long-term follow-up results of study by Cancerand Leukemia Group B. Leukemia 1995; 9: 116-120.
- Shahid A., Kanti R. Interferon in the treatment of hairy-cell leukemia. In Best Pract & Res Clin Haematol 2003; 16 (1): 69-81.
- Else M., Dearden C., Matutes E. et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-740.
- Saven A., Burian C., Koziol J.A., Piro L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-1926.
- Dearden C.E., Matutes E., Hilditch B.L. et al. Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or claridribine. Br J Haematol 1999; 106: 515-519.
- Dietrich S., Glimm H., Andrulis M. et al. BRAF Inhibition in Refractory Hairy-Cell Leukemia N Engl J Med 2012; 366: 21.
- Peyrade F., Re D., Ginet C. et al. Low-dose vemurafenb indused complete remission incase of hairy-cell leukemia with a V600E mutation. Haemotologica 2013; 98 (2): е20-е22.
- Follows G.A., Smis H., Bloxham D.M. et. al. Rapid response of bialetic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 2013; 161 (1): 150-153.
![](/img/style/loading.gif)